AbbVie

News
Imbruvica

AbbVie and J&J claim new Imbruvica okay in US

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) to be approved by the FDA, its tenth indication.

News
AbbVieBuilding

AbbVie wobbles as biosimilars bite Humira

AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly in Europe – weakened cash cow product Humira.

Views & Analysis
Round-up-16x9

R&D roundup – Sage impresses at JP Morgan

One of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling promising data from an up-rated phase III trial of its postpartum